看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
4 g: O4 w. U" a; m( L0 l% G# S4 w4 g- D, v4 O
! F2 B9 c7 F8 p$ `* F0 D }' XCurrently available feasibility data for possible combination strategies. + F* B: T8 g2 p: k/ `- O
————————————————————————————————# J- p; Y% g0 Q
Combination Feasibility according to preliminary data
' \0 u% @! e% r. R2 N——————————————————————————————————
$ r* I3 f& E4 K/ u2 n' P: n% K- \Bevacizumab + sorafenib Yes, reduced dose ' i# u' y$ j, v7 B$ I" {
Bevacizumab + sunitinib† No
7 N3 v# s& |. S; z" c/ EBevacizumab + temsirolimus Yes ( d" ?% {. P" [" T3 y/ v8 u; G
Bevacizumab + everolimus Yes 1 t& A4 d- ~$ V, s h
Sorafenib + sunitinib ?
1 Z9 U( ~. v: }9 JSorafenib + temsirolimus Yes, reduced dose
5 j# j% n+ A& w2 q2 s9 XSorafenib + everolimus Yes, reduced dose
$ J5 u- Q5 a+ u3 WSunitinib + temsirolimus† No , x& S/ Q. O# y+ R# i3 U2 ?
Sunitinib + everolimus ? * \2 [. a! k* q
Temsirolimus + everolimus ?
$ @: l. W8 Q: t' v, G0 B6 u7 v————————————————————
( l* P; X7 ~& {: I8 m) K+ I†Led to US FDA warning./ z; _6 a) u! _4 E
?: As yet unattempted combination.
' e6 N4 {: Q7 g( |/ o |